AR064361A1 - Compuesto derivado de benzamida, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento - Google Patents
Compuesto derivado de benzamida, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamentoInfo
- Publication number
- AR064361A1 AR064361A1 ARP070105631A ARP070105631A AR064361A1 AR 064361 A1 AR064361 A1 AR 064361A1 AR P070105631 A ARP070105631 A AR P070105631A AR P070105631 A ARP070105631 A AR P070105631A AR 064361 A1 AR064361 A1 AR 064361A1
- Authority
- AR
- Argentina
- Prior art keywords
- pain
- alkyl
- halogen
- pain associated
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto derivado de benzamida de la formula (1) o un derivado farmacéuticamente aceptable del mismo, en la que R1 representa halogeno o alquilo C1-4; R2 representa alquilo C1-4 o cloro; R3 representa H, alquilo C1-4 o halogeno; R4 representa H; cada R5 representa independientemente halogeno o alquilo C1-4; m representa 0 o 1; n representa 0, 1 o 2; y X representa O o NH; con la condicion de que cuando n representa 2 y R5 representa halogeno, los grupos R5 junto con el grupo fenilo al que están unidos no formen un resto 2,3-difluorofenilo. Composicion farmacéutica que lo comprende y su uso para la preparacion de un medicamento para el tratamiento de una afeccion que está mediada por la accion, o por la pérdida de accion, de PGE2 en los receptores EP4. La afeccion puede ser dolor articular cronico; dolor musculoesquelético; dolor lumbar y cervical; torceduras y esguinces; dolor neuropático; dolor mantenido simpáticamente; miositis; dolor asociado con cáncer y fibromialgia; dolor asociado con migrana; dolor asociado con la gripe u otras infecciones virales; fiebre reumática; dolor asociado con trastornos funcionales del intestino; dolor asociado con isquemia de miocardio; dolor postoperatorio; dolor de cabeza; dolor de muelas y dismenorrea.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0625098A GB0625098D0 (en) | 2006-12-15 | 2006-12-15 | Novel compounds |
GB0715145A GB0715145D0 (en) | 2007-08-03 | 2007-08-03 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064361A1 true AR064361A1 (es) | 2009-04-01 |
Family
ID=39149241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105631A AR064361A1 (es) | 2006-12-15 | 2007-12-14 | Compuesto derivado de benzamida, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento |
Country Status (21)
Country | Link |
---|---|
US (3) | US8314147B2 (es) |
EP (1) | EP2101751A1 (es) |
JP (1) | JP5069752B2 (es) |
KR (1) | KR20090089868A (es) |
AR (1) | AR064361A1 (es) |
AU (1) | AU2007331471C1 (es) |
BR (1) | BRPI0720254A2 (es) |
CA (1) | CA2672631A1 (es) |
CL (1) | CL2007003640A1 (es) |
CR (1) | CR10849A (es) |
DO (1) | DOP2009000124A (es) |
EA (1) | EA015931B1 (es) |
IL (1) | IL198931A0 (es) |
MA (1) | MA30991B1 (es) |
MX (1) | MX2009006474A (es) |
NO (1) | NO20092314L (es) |
NZ (1) | NZ577109A (es) |
PE (1) | PE20081579A1 (es) |
SG (1) | SG177203A1 (es) |
TW (1) | TW200848014A (es) |
WO (1) | WO2008071736A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009005076A1 (ja) * | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
AU2008343924B2 (en) * | 2007-12-19 | 2013-01-17 | Amgen Inc. | Phenyl acetic acid derivatives as inflammation modulators |
RU2479576C9 (ru) | 2008-05-14 | 2014-03-10 | Астеллас Фарма Инк. | Амидное соединение |
GB0810313D0 (en) * | 2008-06-05 | 2008-07-09 | Glaxo Group Ltd | Novel compounds |
GB0810617D0 (en) * | 2008-06-10 | 2008-07-16 | Glaxo Group Ltd | Novel pharmaceutical |
GB0810615D0 (en) * | 2008-06-10 | 2008-07-16 | Glaxo Group Ltd | Novel pharmaceutical |
MX2012003778A (es) * | 2009-09-29 | 2012-06-01 | Glaxo Group Ltd | Compuestos novedosos. |
CN102596921B (zh) * | 2009-09-29 | 2015-04-29 | 葛兰素集团有限公司 | 新化合物 |
JP2013508282A (ja) | 2009-10-14 | 2013-03-07 | ジェンムス ファーマ インコーポレイティド | ウイルス感染のための併用療法処置 |
NZ607306A (en) * | 2010-07-30 | 2015-03-27 | Allergan Inc | Compounds and methods for skin repair |
US8900571B2 (en) | 2010-08-19 | 2014-12-02 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8894992B2 (en) | 2010-08-19 | 2014-11-25 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8926963B2 (en) | 2010-08-19 | 2015-01-06 | Allergan, Inc. | Compositions and soft tissue replacement methods |
DK2619182T3 (en) | 2010-09-21 | 2017-01-30 | Eisai R&D Man Co Ltd | PHARMACEUTICAL COMPOSITION |
US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
EP2814527A1 (en) * | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
KR20220147691A (ko) | 2013-08-09 | 2022-11-03 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
AU2015227064B2 (en) * | 2014-03-06 | 2017-05-11 | Aratana Therapeutics, Inc. | Crystalline forms of grapiprant |
AR103992A1 (es) | 2015-01-16 | 2017-06-21 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Método para preparar compuestos fenólicos a partir de biomasa |
EP3184505A1 (en) | 2015-12-22 | 2017-06-28 | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO | Method for preparing phenolics using a catalyst |
US20220202774A1 (en) * | 2019-04-09 | 2022-06-30 | Neurobit Science Co., Ltd. | Pharmaceutical composition for prevention or treatment of spinal cord injury or spinal stenosis |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
CN111454150B (zh) * | 2019-12-25 | 2023-03-28 | 南京工业大学 | 一种(s)-2-芳基丙酸酯类化合物的合成方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10265454A (ja) | 1997-01-27 | 1998-10-06 | Ono Pharmaceut Co Ltd | 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤 |
AUPO713297A0 (en) | 1997-06-02 | 1997-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compound |
US6043275A (en) | 1998-04-16 | 2000-03-28 | Ono Pharmaceutical Co., Ltd. | 3,7-dithiaprostanoic acid derivative |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US6586468B1 (en) | 1998-09-14 | 2003-07-01 | Ono Pharmaceutical Co., Ltd. | ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient |
AUPP608898A0 (en) | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
CA2346038A1 (en) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0031315D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
SE0102300D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
CA2478653A1 (en) | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
MXPA04009243A (es) | 2002-04-12 | 2005-06-08 | Pfizer | Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6. |
WO2003103604A2 (en) | 2002-06-01 | 2003-12-18 | Applied Research Systems Ars Holding N.V | Gamma lactams as prostaglandin agonists and use thereof |
AU2003275838A1 (en) | 2002-10-25 | 2004-05-13 | Beunard, Jean-Luc | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
BRPI0406717A (pt) * | 2003-01-10 | 2005-12-20 | Hoffmann La Roche | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção |
CA2514220C (en) | 2003-01-29 | 2012-02-28 | Pharmagene Laboratories Limited | Ep4 receptor antagonists |
EP1663979B1 (en) | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
EP1723132A1 (en) * | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
DE602005015215D1 (de) | 2004-05-04 | 2009-08-13 | Raqualia Pharma Inc | Orthosubstituierte aryl- oder heteroarylamidverbindungen |
CA2565813C (en) | 2004-05-04 | 2010-10-26 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
WO2005116010A1 (en) | 2004-05-26 | 2005-12-08 | Merck Frosst Canada Ltd. | Ep4 receptor agonist, compositions and methods thereof |
WO2006122403A1 (en) | 2005-05-19 | 2006-11-23 | Merck Frosst Canada Ltd. | Quinoline derivatives as ep4 antagonists |
-
2007
- 2007-12-12 JP JP2009540763A patent/JP5069752B2/ja not_active Expired - Fee Related
- 2007-12-12 WO PCT/EP2007/063796 patent/WO2008071736A1/en active Application Filing
- 2007-12-12 EP EP07857459A patent/EP2101751A1/en not_active Withdrawn
- 2007-12-12 SG SG2011091873A patent/SG177203A1/en unknown
- 2007-12-12 US US12/519,219 patent/US8314147B2/en not_active Expired - Fee Related
- 2007-12-12 CA CA002672631A patent/CA2672631A1/en not_active Abandoned
- 2007-12-12 MX MX2009006474A patent/MX2009006474A/es active IP Right Grant
- 2007-12-12 KR KR1020097012174A patent/KR20090089868A/ko not_active Application Discontinuation
- 2007-12-12 AU AU2007331471A patent/AU2007331471C1/en not_active Ceased
- 2007-12-12 NZ NZ577109A patent/NZ577109A/en not_active IP Right Cessation
- 2007-12-12 BR BRPI0720254-7A patent/BRPI0720254A2/pt not_active IP Right Cessation
- 2007-12-12 US US11/954,815 patent/US20080167377A1/en not_active Abandoned
- 2007-12-12 EA EA200970585A patent/EA015931B1/ru not_active IP Right Cessation
- 2007-12-13 TW TW096147555A patent/TW200848014A/zh unknown
- 2007-12-13 PE PE2007001779A patent/PE20081579A1/es not_active Application Discontinuation
- 2007-12-14 CL CL200703640A patent/CL2007003640A1/es unknown
- 2007-12-14 AR ARP070105631A patent/AR064361A1/es not_active Application Discontinuation
-
2009
- 2009-05-25 IL IL198931A patent/IL198931A0/en unknown
- 2009-05-29 DO DO2009000124A patent/DOP2009000124A/es unknown
- 2009-06-09 CR CR10849A patent/CR10849A/es unknown
- 2009-06-15 MA MA31990A patent/MA30991B1/fr unknown
- 2009-06-16 NO NO20092314A patent/NO20092314L/no not_active Application Discontinuation
-
2012
- 2012-10-08 US US13/646,949 patent/US20130261185A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100022650A1 (en) | 2010-01-28 |
IL198931A0 (en) | 2010-02-17 |
AU2007331471B2 (en) | 2013-01-10 |
DOP2009000124A (es) | 2010-03-31 |
US20130261185A1 (en) | 2013-10-03 |
US8314147B2 (en) | 2012-11-20 |
AU2007331471C1 (en) | 2013-07-25 |
MX2009006474A (es) | 2009-06-26 |
BRPI0720254A2 (pt) | 2014-01-07 |
TW200848014A (en) | 2008-12-16 |
CR10849A (es) | 2009-08-12 |
PE20081579A1 (es) | 2009-01-01 |
JP5069752B2 (ja) | 2012-11-07 |
CA2672631A1 (en) | 2008-06-19 |
NZ577109A (en) | 2011-12-22 |
EP2101751A1 (en) | 2009-09-23 |
CL2007003640A1 (es) | 2008-07-11 |
WO2008071736A1 (en) | 2008-06-19 |
NO20092314L (no) | 2009-08-31 |
EA200970585A1 (ru) | 2009-10-30 |
US20080167377A1 (en) | 2008-07-10 |
MA30991B1 (fr) | 2009-12-01 |
EA015931B1 (ru) | 2011-12-30 |
AU2007331471A1 (en) | 2008-06-19 |
JP2010513242A (ja) | 2010-04-30 |
SG177203A1 (en) | 2012-01-30 |
KR20090089868A (ko) | 2009-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064361A1 (es) | Compuesto derivado de benzamida, composicion farmaceutica que lo comprende y su uso para la preparacion de un medicamento | |
AR111820A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue | |
UY38602A (es) | Compuestos tricíclicos condensados | |
AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
RS20070461A (en) | Injectable compositions and process of preparation of such compositions | |
UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
ME00558A (en) | Pyrazole derivatives for treating hiv | |
TN2010000026A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
CL2011001413A1 (es) | Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana. | |
UY31344A1 (es) | Metansulfonamidas n-(3-ter-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-2-metoxi-aril) sustituidas, solvatos, hidratos, formas cristalinas y sus sales farmacéuticamente aceptables,proceso de preparación,composiciones y aplicaciones. | |
UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
EA200400616A1 (ru) | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β | |
AR030152A1 (es) | Uso de benzimidazoles e imidazopiridinas para la preparacion de medicamentos para el tratamiento de infecciones virales, benzimidazoles e imidazopiridinas, productos y composiciones farmaceuticas que los comprenden y procesos para prepararlos | |
EA200501326A1 (ru) | Пиримидины и триазины, ингибирующие репликацию вич | |
CL2009001554A1 (es) | Compuestos derivados de 4-(sulfonilaminoalquilamino)-n-fenil-n'-hidroxi-1,2,5-oxadiazol-3-carboximidamida; formas cristalinas; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades tales como cancer, infeccion viral, depresion, entre otras. | |
EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
ECSP11010878A (es) | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv. | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR046202A1 (es) | Compuestos nucleosidicos para el tratamiento de infecciones virales | |
DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
DK1891038T3 (da) | Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer | |
UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |